ES2114073T3 - Regeneracion del higado inducida por morfogenes. - Google Patents

Regeneracion del higado inducida por morfogenes.

Info

Publication number
ES2114073T3
ES2114073T3 ES93922700T ES93922700T ES2114073T3 ES 2114073 T3 ES2114073 T3 ES 2114073T3 ES 93922700 T ES93922700 T ES 93922700T ES 93922700 T ES93922700 T ES 93922700T ES 2114073 T3 ES2114073 T3 ES 2114073T3
Authority
ES
Spain
Prior art keywords
liver
compositions
methods
mammal
devices
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93922700T
Other languages
English (en)
Inventor
Thangavel Kuberasampath
David C Rueger
Hermann Oppermann
Roy H L Pang
Charles M Cohen
Engin Ozkaynak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Biomolecules Inc
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Application granted granted Critical
Publication of ES2114073T3 publication Critical patent/ES2114073T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/24—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2310/00—Prostheses classified in A61F2/28 or A61F2/30 - A61F2/44 being constructed from or coated with a particular material
    • A61F2310/00005—The prosthesis being constructed from a particular material
    • A61F2310/00365—Proteins; Polypeptides; Degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN METODOS DE TRATAMIENTO, COMPOSICIONES E INSTRUMENTOS PARA MANTENER LA FUNCION DEL HIGADO EN UN MAMIFERO, INCLUYENDO MEDIOS PARA REGENERAR EL TEJIDO HEPATICO PERDIDO O DAÑADO, DISPOSITIVOS PARA INCREMENTAR LA VIABILIDAD E INTEGRACION DE TRANSPLANTES DE ORGANO Y TEJIDO HEPATICO Y DISPOSITIVOS PARA CORREGIR LAS DEFICIENCIAS FUNCIONALES DEL HIGADO, INCLUYENDO MEDIOS PARA INCREMENTAR LAS DISMINUIDAS FUNCIONES DEL HIGADO DEBIDAS A ENFERMEDAD O DAÑO TISULAR. LOS METODOS, COMPOSICIONES Y DISPOSITIVOS DEL INVENTO EN CONJUNTO PROPORCIONAN UNA CONCENTRACION DE MORFOGEN TERAPEUTICAMENTE EFECTIVA A LAS CELULAS HEPATICAS A TRATAR. TAMBIEN SE DESCUBREN METODOS Y COMPOSICIONES UTILES EN TERAPIA GENETICA O PROTOCOLOS DE ADMINISTRACION DE DROGAS PARA CORRECCION DE DEFICIENCIA DE PROTEINAS EN UN MAMIFERO.
ES93922700T 1992-09-16 1993-09-16 Regeneracion del higado inducida por morfogenes. Expired - Lifetime ES2114073T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94623892A 1992-09-16 1992-09-16
US2933593A 1993-03-04 1993-03-04
US4051093A 1993-03-31 1993-03-31
PCT/US1993/008808 WO1994006449A2 (en) 1992-09-16 1993-09-16 Morphogen-induced liver regeneration

Publications (1)

Publication Number Publication Date
ES2114073T3 true ES2114073T3 (es) 1998-05-16

Family

ID=27363459

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93922700T Expired - Lifetime ES2114073T3 (es) 1992-09-16 1993-09-16 Regeneracion del higado inducida por morfogenes.

Country Status (10)

Country Link
EP (1) EP0661987B1 (es)
JP (1) JP3973050B2 (es)
AT (1) ATE162078T1 (es)
AU (1) AU681356B2 (es)
CA (1) CA2144514C (es)
DE (1) DE69316379T2 (es)
DK (1) DK0661987T3 (es)
ES (1) ES2114073T3 (es)
GR (1) GR3026602T3 (es)
WO (1) WO1994006449A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150328A (en) 1986-07-01 2000-11-21 Genetics Institute, Inc. BMP products
CA2363965C (en) 1991-03-11 2010-05-18 Curis, Inc. Protein-induced morphogenesis
US6287816B1 (en) * 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
US6291206B1 (en) 1993-09-17 2001-09-18 Genetics Institute, Inc. BMP receptor proteins
DE69434651T2 (de) 1993-12-07 2007-03-08 Genetics Institute, Inc., Cambridge Bmp-12, bmp-13 und diese enthaltende sehne-induzierende zusammensetzungen
US5738848A (en) * 1994-02-16 1998-04-14 Kamada; Naoshi Immunosuppressive compounds and method of preparing same
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
AU757969B2 (en) * 1996-05-06 2003-03-13 Stryker Corporation Therapies for chronic renal failure
AU7142000A (en) * 1996-05-06 2001-01-25 Curis, Inc. Morphogen treatment for chronic renal failure
WO1998050060A1 (en) 1997-05-05 1998-11-12 Creative Biomolecules, Inc. Therapies for acute renal failure
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
CA2291514C (en) 1997-05-30 2011-07-12 Mariel Therapeutics, Inc. Methods for evaluating tissue morphogenesis and activity
EP0998558A1 (en) * 1997-07-10 2000-05-10 Genetics Institute, Inc. Wa545 compositions
US7147839B2 (en) 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity
US6727224B1 (en) 1999-02-01 2004-04-27 Genetics Institute, Llc. Methods and compositions for healing and repair of articular cartilage
ATE271886T1 (de) 1999-10-15 2004-08-15 Inst Genetics Llc Hyaluronsäure enthaltende zusammensetzungen zur abgabe osteogener proteine
WO2002099037A2 (en) 2001-06-01 2002-12-12 Wyeth Compositions and methods for systemic administration of sequences encoding bone morphogenetic proteins
TWI267378B (en) 2001-06-08 2006-12-01 Wyeth Corp Calcium phosphate delivery vehicles for osteoinductive proteins
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
WO2005097825A2 (en) * 2004-03-31 2005-10-20 Xencor, Inc. Bmp-7 variants with improved properties
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
JP2008169116A (ja) * 2005-04-18 2008-07-24 Tokyo Medical & Dental Univ Ｂｍｐ−７を含む抗ｃ型肝炎ウイルス剤
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
WO2020086580A1 (en) 2018-10-22 2020-04-30 Carlson William D Therapeutic combinations of tdfrps and additional agents and methods of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4396601A (en) 1980-03-26 1983-08-02 The Regents Of The University Of Calif. Gene transfer in intact mammals
AU6131086A (en) 1985-07-05 1987-01-30 Whitehead Institute For Biomedical Research Epithelial cells expressing foreign genetic material
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US4968590A (en) 1988-04-08 1990-11-06 Stryker Corporation Osteogenic proteins and polypeptides
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
KR900700617A (ko) * 1988-04-08 1990-08-16 브루스 엠. 에이센 뼈 및 연골 유도 조성물
HU201095B (en) 1988-06-14 1990-09-28 Richter Gedeon Vegyeszet New peptides inhibiting the activity of the immune system and pharmaceutical compositions comprising same, as well as process for producing these peptides and compositions
US5104858A (en) 1988-09-29 1992-04-14 Yale University Sensitizing multidrug resistant cells to antitumor agents
US5068323A (en) 1989-04-21 1991-11-26 Merck & Co., Inc. Thermally re-arranged FK-506 derivatives having immunosuppressant activity
JP3073766B2 (ja) 1989-04-25 2000-08-07 チルドレンズ メディカル センター コーポレイション 重合マトリックス上の大容量の細胞の移植方法
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
EP0564502B1 (en) * 1990-11-27 2002-01-30 The American National Red Cross Tissue sealant and growth factor containing compositions that promote accelerated wound healing
AU660019B2 (en) * 1991-03-11 1995-06-08 Stryker Corporation Protein-induced morphogenesis
CA2116562C (en) * 1991-08-30 1999-04-13 Thangavel Kuberasampath Morphogen-induced modulation of inflammatory response
US9103603B2 (en) 2009-10-28 2015-08-11 Tai-Her Yang Thermal conductive cylinder installed with U-type core piping and loop piping

Also Published As

Publication number Publication date
EP0661987A1 (en) 1995-07-12
WO1994006449A2 (en) 1994-03-31
JPH08501558A (ja) 1996-02-20
DE69316379D1 (de) 1998-02-19
AU681356B2 (en) 1997-08-28
DE69316379T2 (de) 1998-07-30
CA2144514A1 (en) 1994-03-31
DK0661987T3 (da) 1998-09-14
ATE162078T1 (de) 1998-01-15
EP0661987B1 (en) 1998-01-14
AU5162393A (en) 1994-04-12
WO1994006449A3 (en) 1994-09-01
GR3026602T3 (en) 1998-07-31
JP3973050B2 (ja) 2007-09-05
CA2144514C (en) 2002-03-26

Similar Documents

Publication Publication Date Title
DK0661987T3 (da) Morphogeninduceret leverregeneration
DE69534878D1 (de) Neuartige adenovirale vektoren, verpackungsszellinien, rekombinante adenoviren und verfahren
FI972781A7 (fi) Deskarboetoksiloratadiinin (DCL) tai sen farmaseuttisesti hyväksyttävän suolan käyttö valmistettaessa farmaseuttista tuotetta
SV1995000007A (es) Derivados del acido micofenolico 5-substituidos.
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
BR9507506A (pt) Processo para exterminar uma célula processo para tratamento de càncer composição e kit terapéutico
DK0853660T3 (da) Fremgangsmåde til opbevaring af infektiøse rekombinante virusser, vandig virussuspension og anvendelse som lægemiddel
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
TR200102648T2 (tr) Büyümeyi destekleyen bileşimler
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
DE69630890D1 (de) Peptid-immitierende substanzen in der krebstherapie
ATE242639T1 (de) Morphogen induzierte nerven wiederherstellung und wiedergutmachung.
HUP0200152A2 (hu) KQT1 csatornák gátlóinak alkalmazása parazita férgek és ektoparaziták által okozott betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
DK0817646T3 (da) Fremgangsmåder til behandling af inflammation og præparater derfor
EP0214017A3 (en) Use of n,n,-dimethylbiguanid p-chorophenoxyacetate in the treatment of neuropathies and nerval degeneration
DE69725882D1 (de) Adenovirus e4 proteine für induktion von zelltod
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
ATE415978T1 (de) Sequentielle verabreichung von cpt-11 und apo-2l polypeptid
FI20020197A0 (fi) Yhdistelmä akuutin myokardiilisen infarktin hoitoon
DK0673250T3 (da) Ophthalmiske præparater omfattende emedastin og deres anvendelse til behandling af allergisk conjunctivitis
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
AR037496A1 (es) Uso novedoso del 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y sus sales fisiologicamente aceptables
DK147088D0 (da) Middel til behandling af virale infektioner i mennesker
ATE548048T1 (de) Oncomodulin zur behandlung von neurologishen erkrankungen
ATE238796T1 (de) Nukleosidderivative in kombinationspräparaten zur behandlung von hsv krankheiten

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 661987

Country of ref document: ES